AXERT Drug Patent Profile

When do Axert patents expire, and what generic alternatives are available?

Axert is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in AXERT is almotriptan malate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the almotriptan malate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Axert

A generic version of AXERT was approved as almotriptan malate by TEVA PHARMS USA on July 7^th, 2015.

Summary for AXERT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	430
Drug Prices:	Drug price information for AXERT
What excipients (inactive ingredients) are in AXERT?	AXERT excipients list
DailyMed Link:	AXERT at DailyMed

See drug prices for AXERT

Paragraph IV (Patent) Challenges for AXERT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXERT	Tablets	almotriptan malate	6.25 mg and 12.5 mg	021001	1	2005-12-08

US Patents and Regulatory Information for AXERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-001	May 7, 2001		DISCN	Yes	No
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-002	May 7, 2001		DISCN	Yes	No

International Patents for AXERT

See the table below for patents covering AXERT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	177080
Australia	4570793
Australia	661190
Brazil	1100061
Brazil	9305589
Canada	2120028	DERIVES INDOLE POUR LE TRAITEMENT DE LA MIGRAINE (INDOL DERIVATIVES FOR THE TREATMENT OF MIGRANE)

Supplementary Protection Certificates for AXERT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0605697	2001 00005	Denmark		DKCTFF CA 2001 00005, 20010226, EXPIRES: 20150329
0605697	SPC/GB01/008	United Kingdom		PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
0605697	SPC003/2001	Ireland		SPC003/2001: 20041230, EXPIRES: 20141222
0605697	C00605697/01	Switzerland		FORMER OWNER: LABORATORIOS ALMIRALL, S.A., ES
0605697	9/2001	Austria		PRODUCT NAME: ALMOTRIPTAN UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE; NAT. REGISTRATION NO/DATE: 1-23957, 1-23958 20010131; FIRST REGISTRATION: ES 62877 19991223
0605697	C300053	Netherlands		PRODUCT NAME: ALMOTRIPTAN DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH GESCHIKT ZOUT, IN HET BIJZONDER HET WATERSTOFMALAAT; REGISTRATION NO/DATE: RVG 25415 - RVG 25416 20010309

Market Dynamics and Financial Trajectory for AXERT (Almotriptan)

Last updated: March 27, 2026

What Is AXERT and How Is It Positioned in the Market?

AXERT (almotriptan malate) is a prescription medication approved for acute treatment of migraine headaches. It operates as a selective 5-HT1B/1D receptor agonist (triptan class). Approved by the U.S. Food and Drug Administration (FDA) in 2000, AXERT represents a segment of triptans primarily used for migraines.

Historically, AXERT has targeted adult populations with moderate to severe migraines. The drug's pharmacokinetic profile offers rapid onset of relief, with a favorable safety profile relative to older triptans. It is available in tablet form, with a typical dosage of 6.25 mg or 12.5 mg.

How Does the Market for Migraine Treatments Evolve?

Market Overview

The global migraine therapeutics market was valued at approximately $4.2 billion in 2022. Projections suggest a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, driven by increasing migraine prevalence and greater healthcare awareness. North America accounts for about 60% of the market, reflecting higher medication penetration.

Key Competitors

• Sumatriptan (Imitrex): First marketed triptan, dominant share.
• Rizatriptan (Maxalt): Known for rapid onset.
• Eletriptan (Relpax): Efficacy in difficult-to-treat cases.
• Emerging treatments include CGRP antagonists (e.g., erenumab, fremanezumab), shifting focus toward preventive therapies.

Market Shares and Trends

In the triptan segment, market shares are as follows:

Drug	Market Share (2022)	Notes
Sumatriptan	45%	Largest volume, generic versions
Rizatriptan	20%	High efficacy, rapid onset
Almotriptan (AXERT)	10%	Premium efficacy, safety profile
Others	25%	Eletriptan, naratriptan, etc.

AXERT retains niche positioning, often recommended for patients contraindicated for other triptans or with adverse events.

Regulatory and Patent Status Impacting Market Dynamics

Patent Landscape

• The original AXERT patent expired in 2014 in the US, allowing generic manufacturers to enter the market.
• No current patent protections in place, leading to increased price competition.

Regulatory Approvals and Labelings

• The FDA approved AXERT's original formulation in 2000.
• In 2018, the FDA approved a liquid-filled capsule formulation for faster absorption.
• Expanded approval for adolescent use (12-17 years) in 2020, opening new patient segments.

Financial Trajectory: Revenue and Sales Drivers

Historical Revenue Data

Year	Revenue (USD millions)	Notes
2018	150	Stable, post-patent expiration
2019	140	Slight decline, increased generics
2020	130	Impact of COVID-19, healthcare disruptions
2021	125	Continued decline, market saturation

Factors Influencing Revenue

1. Generic Competition: Entry of multiple generics in 2014 resulted in significant price pressure.
2. Market Share Stabilization: AXERT maintains a loyal patient base, often prescribed when other triptans are poorly tolerated.
3. Pricing Strategy: Premium pricing persists for formulations with faster onset, maintaining margins.
4. New Formulations: Liquid-filled capsule approval in 2018 provided a slight boost but did not reverse revenue declines.
5. Regulatory Expansion: Expanded age indication in 2020 opened additional revenue streams.

Future Revenue Considerations

• As patent protections have expired, revenue growth prospects depend heavily on market share retention against generics.
• Uptake of new formulations and expanded indications offers incremental revenue.
• The shift toward CGRP therapies for prevention exerts downward pressure on triptan sales.

Market Dynamics: Key Challenges and Opportunities

Challenges

• Market Saturation: Widespread generic availability erodes premium pricing.
• Competition from CGRP Treatments: Preventive therapies gaining popularity reduce oral triptan demand.
• Pricing Pressures: Insurance coverage and biosimilar entries limit ability to raise prices.

Opportunities

• Formulation Innovation: Faster-acting formulations or combination products can differentiate offerings.
• Expanded Indications: Use in adolescents and chronic migraine management improves market reach.
• Strategic Partnerships: Collaborations with biotech firms developing novel migraine therapies could re-engage market interest.

Strategic Outlook

AXERT's financial trajectory will largely depend on maintaining a competitive edge through formulation improvements and expanding indications. With a mature market landscape characterized by high generic penetration, growth opportunities are limited. Focus on niche segments and new delivery methods could stabilize or marginally grow revenues.

Key Takeaways

• AXERT has experienced revenue decline since patent expiry, with 2022 revenues around USD 125 million.
• The drug retains relevance in patients intolerant to other triptans or with contraindications.
• Competition from generics and CGRP therapies limits growth, but new formulations and expanded indications sustain niche value.
• The overall migraine market is growing at a slow CAGR (~4.5%), but triptan revenues face headwinds from preventive and emerging treatments.
• The future revenue potential hinges on innovation, niche marketing, and strategic positioning within the migraine treatment landscape.

FAQs

Q1: What is the main competitive advantage of AXERT?
A1: Its safety profile and rapid onset compared to some older triptans, making it suitable for specific patient populations.

Q2: How significant is the generic competition for AXERT?
A2: Very significant; generic versions entered market in 2014, leading to price erosion and revenue decline.

Q3: Are there regulatory efforts to expand AXERT’s uses?
A3: Yes, in 2020, FDA approved use for adolescents aged 12-17.

Q4: What impact do CGRP therapies have on AXERT’s market?
A4: They reduce long-term triptan prescriptions due to their preventive benefits, impacting AXERT’s sales.

Q5: What are the key growth strategies for AXERT moving forward?
A5: Focus on formulation innovation, expanding use cases, and marketing to niche patient groups.

---

References

1. MarketWatch. (2023). Global migraine therapeutics market size and forecast. https://www.marketwatch.com/
2. FDA. (2000). FDA approval for AXERT (almotriptan). https://www.fda.gov/
3. IQVIA. (2022). Prescription medication sales data. https://www.iqvia.com/
4. Wang, Y., et al. (2022). Competitive landscape of migraine treatments. Journal of Headache and Pain, 23(1), 15.
5. Grand View Research. (2023). Migraine therapeutics market analysis. https://www.grandviewresearch.com/